Hyperthermic isolated regional perfusion with cisplatin in the local treatment of spontaneous canine osteosarcoma: Assessment of short‐term effects
- 19 July 1995
- journal article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 59 (3) , 169-176
- https://doi.org/10.1002/jso.2930590307
Abstract
To increase the effect of cisplatin on locoregional osteosarcoma, the shortterm effect of hyperthermic isolated regional perfusion (HIRP) with cisplatin (30 mg/L extremity volume) was studied in 28 dogs with spontaneous osteogenic sarcoma, using clinical, radiological, and histological parameters. Thirty days postoperatively, mortality was 14.3%. Total platinum levels at the start of perfusion were 28.2 ± 14.3 mg/L. A significant improvement (P < 0.001) in clinical score was observed in the overall group at 6 and 12 weeks after perfusion. The radiological parameter showed a stationary X‐ray 2 weeks after perfusion and an improved X‐ray 6 weeks after perfusion. Overall histological scores showed a moderate effect according to the Huvos classification. No additional therapeutic effect, according to the three parameters, could be demonstrated by increasing the perfusate temperature by 1°C. HIRP with cisplatin is feasible in the local treatment of spontaneous osteosarcoma in dogs with acceptable locoregional toxicity. However, the histological results were modest, with none of the dogs showing a complete response 6 weeks after perfusion. Therefore, the search for the ideal perfusion agent with substantial contribution to the limb‐sparing treatment in human osteosarcoma continues.Keywords
This publication has 24 references indexed in Scilit:
- Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremitiesBritish Journal of Cancer, 1992
- Osteosarcoma: Clinical Features and Evolving Surgical and Chemotherapeutic StrategiesPediatric Clinics of North America, 1991
- Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.Journal of Clinical Oncology, 1988
- Isolation perfusion with cisplatin for malignant melanoma of the limbsCancer, 1987
- Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.Journal of Clinical Oncology, 1987
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityNew England Journal of Medicine, 1986
- Radiographic changes in primary osteogenic sarcoma following intensive chemotherapy. Radiological-pathological correlation in 63 patients.Radiology, 1982
- The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcomaCancer, 1975
- The therapy of osteogenic sarcoma: Current status and thoughts for the futureJournal of Surgical Oncology, 1972
- Sarcomata of the Osteogenic Series (Osteosarcoma, Fibrosarcoma, Chondrosarcoma, Parosteal Osteogenic Sarcoma, and Sarcomata Arising in Abnormal Bone)Journal of Bone and Joint Surgery, 1966